Nexstim Plc (NXTMS.ST)
| Previous close | 36.40 |
| Open | 36.40 |
| Bid | 35.60 x 0 |
| Ask | 36.50 x 0 |
| Day's range | 35.50 - 36.60 |
| 52-week range | 15.72 - 98.27 |
| Volume | 388 |
| Avg. volume | 3,184 |
| Market cap | 24.487B |
| Beta (5Y monthly) | 2.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.01 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Nexstim Receives an NBS System Upgrade Order from a University Hospital in Finland
Press Release, Helsinki, 16 July 2021 at 9:00 PM (EEST) Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received a new NBS System upgrade order from a university hospital customer in Finland. This is an existing customer for Nexstim and the system will be used for both for pre-surgical mapping of the speech and motor cortices of the brain and to treat Major Depressive Disorder (MDD). Nexstim’s NBS System with SmartFocus® nTMS is highly differentiated from other
- Globe Newswire
Nexstim Plc provides an update on the pilot study in chronic pain treatment at Helsinki University Hospital
Company announcement, Inside information, Helsinki, 1 July 2021 at 14.00 (EET) Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") provides an update on the pilot study on the use of accelerated iTBS protocol in treatment of chronic neuropathic pain with Nexstim NBT® System at Helsinki University Hospital. Nexstim announced on 25 September 2020 that the pilot study is starting and estimated that the patient treatments in the study of five to ten patients would be completed in first half
- Globe Newswire
Nexstim Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater than 50%
Press Release, Helsinki, June 21, 2021 at 10:30 AM (EEST) Nexstim Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater than 50% Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") reports very promising clinical outcomes of the 187 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD). Treatment outcomes of these 187 patients were very good: 50.3% were in remission at end of treatment a
